{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:05:13Z","timestamp":1789761913982,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.urolonc.2026.07.032","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T10:31:19Z","timestamp":1787394679000},"page":"624-632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["miR-638 Upregulation in Serum and Tissues Functions as a Diagnostic and Prognostic Biomarker and Facilitates Prostate Cancer Progression"],"prefix":"10.1016","volume":"44","author":[{"given":"Lei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2829-7105","authenticated-orcid":false,"given":"Jingyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.urolonc.2026.07.032_bib0001","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cpet.2026.02.003","article-title":"Novel theranostic targets for prostate cancer beyond prostate-specific membrane antigen","volume":"21","author":"Heidari","year":"2026","journal-title":"PET clinics."},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.032_bib0002","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41698-026-01368-3","article-title":"Genomic landscape and precision therapy in prostate cancer: current status and future directions","volume":"10","author":"Ligon","year":"2026","journal-title":"NPJ precision oncology."},{"issue":"12","key":"10.1016\/j.urolonc.2026.07.032_bib0003","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/14737159.2021.1996227","article-title":"Long non-coding RNAs and their potential impact on diagnosis, prognosis, and therapy in prostate cancer: racial, ethnic, and geographical considerations","volume":"21","author":"Morgan","year":"2021","journal-title":"Expert Rev Mol Diagn."},{"key":"10.1016\/j.urolonc.2026.07.032_bib0004","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13062-026-00776-6","article-title":"The miR-143\/145 cluster in prostate cancer: molecular regulation, context-dependent functions, and medical implications","volume":"21","author":"Stope","year":"2026","journal-title":"Biol Direct."},{"key":"10.1016\/j.urolonc.2026.07.032_bib0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bbrc.2021.08.037","article-title":"MiR-1207-5p targets PYCR1 to inhibit the progression of prostate cancer","volume":"575","author":"Xu","year":"2021","journal-title":"Biochem Biophys Res Commun."},{"issue":"12","key":"10.1016\/j.urolonc.2026.07.032_bib0006","first-page":"2564","article-title":"miR-338-3p targets RAB23 and suppresses tumorigenicity of prostate cancer cells","volume":"8","author":"Wang","year":"2018","journal-title":"Am J Cancer Res."},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.032_bib0007","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2025.2545653","article-title":"MiR-135a-3p inhibits the progression of prostate cancer by targeting TLR4","volume":"26","author":"Li","year":"2025","journal-title":"Cancer Biol Ther."},{"key":"10.1016\/j.urolonc.2026.07.032_bib0008","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/cells11233776","article-title":"LncRNA\/miRNA\/mRNA network introduces novel biomarkers in prostate cancer","volume":"11","author":"Taheri","year":"2022","journal-title":"Cells."},{"issue":"11","key":"10.1016\/j.urolonc.2026.07.032_bib0009","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1442-2042.2012.03082.x","article-title":"Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma","volume":"19","author":"Sanders","year":"2012","journal-title":"Int J Urol."},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.032_bib0010","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2174\/2211536609666201106090458","article-title":"Serum levels of miR-223-3p and miR-223-5p in prostate diseases","volume":"9","author":"D\u00fclgero\u011flu","year":"2020","journal-title":"MicroRNA."},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.032_bib0011","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.bbrc.2014.10.064","article-title":"U6 is not a suitable endogenous control for the quantification of circulating microRNAs","volume":"454","author":"Xiang","year":"2014","journal-title":"Biochem Biophys Res Commun."},{"issue":"5","key":"10.1016\/j.urolonc.2026.07.032_bib0012","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1261\/rna.939908","article-title":"Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues","volume":"14","author":"Peltier","year":"2008","journal-title":"RNA"},{"issue":"25","key":"10.1016\/j.urolonc.2026.07.032_bib0013","first-page":"59","article-title":"Gleason grading system, modifications and additions to the original scheme","volume":"3","author":"Epstein","year":"2010","journal-title":"J Urol."},{"key":"10.1016\/j.urolonc.2026.07.032_bib0014","series-title":"Multivariable analysis: a practical guide for clinicians and public health researchers","author":"Katz","year":"2011"},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.032_bib0015","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3233\/CBM-201600","article-title":"The discriminative ability of Prostate Health Index to detect prostate cancer is enhanced in combination with miR-222-3p","volume":"30","author":"T\u00f6lle","year":"2021","journal-title":"Cancer Biomark."},{"issue":"2","key":"10.1016\/j.urolonc.2026.07.032_bib0016","first-page":"81","article-title":"The evolving role of PSA in prostate cancer screening: revisiting the evidence in the era of personalized medicine","volume":"7","author":"Filella","year":"2026","journal-title":"Adv Lab Med\/Av Med Lab"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.032_bib0017","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1186\/s12885-025-14505-1","article-title":"The research progress on diagnostic indicators related to prostate-specific antigen gray-zone prostate cancer","volume":"25","author":"Ahamed","year":"2025","journal-title":"BMC Cancer."},{"issue":"15","key":"10.1016\/j.urolonc.2026.07.032_bib0018","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025441","article-title":"Prognostic and clinicopathological significance of miR-638 in cancer patients: a meta-analysis","volume":"100","author":"Hu","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.urolonc.2026.07.032_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153351","article-title":"Dysregulation of miR-638 in the progression of cancers","volume":"220","author":"Chong","year":"2021","journal-title":"Pathol Res Pract"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.032_bib0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1756-9966-31-38","article-title":"Circulating microRNAs in cancer: origin, function and application","volume":"31","author":"Ma","year":"2012","journal-title":"J Exp Clin Cancer Res."},{"issue":"12","key":"10.1016\/j.urolonc.2026.07.032_bib0021","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12032-014-0295-y","article-title":"Cell-free microRNAs as cancer biomarkers: the odyssey of miRNAs through body fluids","volume":"31","author":"Javidi","year":"2014","journal-title":"Med Oncol."},{"issue":"3","key":"10.1016\/j.urolonc.2026.07.032_bib0022","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.celrep.2014.06.064","article-title":"Characterization of dual PTEN and p53-targeting microRNAs identifies microRNA-638\/Dnm2 as a two-hit oncogenic locus","volume":"8","author":"Tay","year":"2014","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.urolonc.2026.07.032_bib0023","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1038\/s12276-022-00887-w","article-title":"The equilibrium of tumor suppression: dUBs as active regulators of PTEN","volume":"54","author":"Christine","year":"2022","journal-title":"Exp Mol Med."},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.032_bib0024","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal transduct target ther."},{"key":"10.1016\/j.urolonc.2026.07.032_bib0025","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2017.01.009","article-title":"MiRNA-638 promotes autophagy and malignant phenotypes of cancer cells via directly suppressing DACT3","volume":"390","author":"Ren","year":"2017","journal-title":"Cancer Lett."},{"issue":"21","key":"10.1016\/j.urolonc.2026.07.032_bib0026","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70354","article-title":"Important roles of PI3K\/AKT signaling pathway and relevant inhibitors in prostate cancer progression","volume":"13","author":"Wang","year":"2024","journal-title":"Cancer medicine."},{"key":"10.1016\/j.urolonc.2026.07.032_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155134","article-title":"The emerging role of non-coding RNAs in the wnt\/\u03b2-catenin signaling pathway in prostate Cancer","volume":"254","author":"Kazmi","year":"2024","journal-title":"Pathol Res Pract."}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926006605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926006605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:12:08Z","timestamp":1789758728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926006605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1078143926006605"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.032","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"miR-638 Upregulation in Serum and Tissues Functions as a Diagnostic and Prognostic Biomarker and Facilitates Prostate Cancer Progression","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}